X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-announces-addition-of-city-of-hope-to-umns-phase-1-trial-of-lymphir-in-combination-with-car-t-for-the-treatment-of-b-cell-lymphoma-302113959.html
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-ld-micro-invitational-xiv-investor-conference-302108125.html
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-announces-fda-acceptance-of-the-bla-resubmission-of-lymphir-denileukin-diftitox-for-the-treatment-of-adults-with-relapsed-or-refractory-cutaneous-t-cell-lymphoma-302090911.html
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-secures-2-4-million-through-new-jersey-economic-development-program-302081639.html
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-announces-filing-of-form-s-3-shelf-registration-statement-to-replace-expiring-prior-shelf-registration-302070667.html
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-upcoming-bio-ceo-and-sidoti-investor-conferences-302069457.html
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-reports-fiscal-first-quarter-2024-financial-results-and-provides-business-update-302062303.html
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-resubmits-the-biologics-license-application-of-lymphir-denileukin-diftitox-for-the-treatment-of-adults-with-relapsed-or-refractory-cutaneous-t-cell-lymphoma-302061089.html
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-announces-nomination-of-pharmaceutical-executive-robert-j-smith-to-its-board-of-directors-302041672.html
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-completes-enrollment-in-pivotal-phase-3-trial-of-its-mino-lok-therapeutic-to-salvage-catheters-302024218.html
Market Place
Share 
